Beta Bionics(NASDAQ) BBNX

Market Cap$715.34M

Since IPO (2025)-33%

5 YearN/A

1 Year+5%

1 Month-2%

$16.34

+2.77%

+0.44Today

After hours$16.40+$0.06 (+0.37%)

Beta Bionics last closing stock price
Metric	Price	Date
Last close	USD 15.90	2026-08-07

Beta Bionics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+23.93%	USD 12.83	2026-07-31
1 month	-1.73%	USD 16.18	2026-07-08
3 month	+64.77%	USD 9.65	2026-05-08
Year to date	-47.82%	USD 30.47	2025-12-31
1 year	+5.37%	USD 15.09	2025-08-07
Since inception	-32.71%	USD 23.63	2025-01-30

Beta Bionics Financials at a Glance

Market Cap

$715.34M

Revenue (TTM)

$119.01M

Net Income (TTM)

-$72.97M

EPS (TTM)

-$1.65

P/E Ratio

-9.65

Dividend

$0.00

Beta (Volatility)

1.53 (High)

Dividend

$0.00

Beta (Volatility)

1.53 (High)

Price

$16.34

Volume

1,316,058.365

Open

$15.66

Price

$16.34

Volume

1,316,058.365

Open

$15.66

Previous Close

$16.40

Daily Range

$15.64 - $16.86

52-Week Range

$8.80 - $32.71

Estimated Earnings Date

Oct 27, 2026

Dividend

$0.00

Beta (Volatility)

1.53 (High)

Price

$16.34

Volume

1,316,058.365

Open

$15.66

Previous Close

$16.40

Daily Range

$15.64 - $16.86

52-Week Range

$8.80 - $32.71

Estimated Earnings Date

Oct 27, 2026

BBNX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Beta Bionics

Beta Bionics helps people with diabetes manage their health automatically. The company makes a device that decides insulin doses without manual work. This system removes the need for users to count every carbohydrate intake.

What the Company Sells

iLet Bionic Pancreas: Wearable insulin delivery device that uses algorithms to determine doses autonomously; cleared for adults and children.
Single-use Products: Disposable insulin cartridges and infusion sets that users replace every two to three days.
DME Channel: Sales through durable medical equipment distributors where insurers pay a high upfront cost for the device.
PBP Channel: Pharmacy sales model with low upfront costs and higher supply costs; represented 39% of net sales in Q1 2026.

Recent Growth and Partnerships

Signed a licensing deal with Xeris Pharmaceuticals, Inc. in May 2024 to develop a system using both insulin and glucagon.
Collaborated with DexCom, Inc. and Abbott Diabetes Care Inc. to link the iLet platform with popular glucose sensors.
Completed a clinical trial in Canada in September 2025 to test a new glucagon product candidate.
Initiated a feasibility trial in early 2026 to evaluate an integrated system that delivers two different hormones.

Why It Stands Out

The company operates a 50,000 square foot manufacturing site in Irvine, California to support its production needs. Its technology differentiates itself by requiring only a user's body weight to start automated insulin delivery.

Tracking Financial Growth

Net sales reached $27.6 million in Q1 2026, up 56.6% from Q1 2025.
Gross profit hit $16.4 million in Q1 2026, an 83.2% increase year-over-year.
Operating loss deepened to $24.3 million in Q1 2026, a 30.2% worsening from the previous year.
Net loss narrowed to $21.9 million in Q1 2026, improving by 23.6% compared to Q1 2025.

Evolution of the Business

Beta Bionics has moved from a research-focused firm to a commercial provider of automated insulin systems. The company is now focusing on expanding its pharmacy sales and developing bihormonal treatment options.

AI Generated • May 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

423

CEO

Sean Thomas Saint

Website

www.betabionics.com

Headquarters

Irvine, CA 92618, US

BBNX Financials

Key Financial Metrics (TTM)

Gross Margin

58.31%

Operating Margin

-69.75%

Net Income Margin

-61.32%

Return on Equity

-26.30%

Return on Capital

-24.31%

Return on Assets

-24.96%

Earnings Yield

-10.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$715.34M

Shares Outstanding

44.99M

Volume

1.32M

Avg. Volume

1.08M

Financials (TTM)

Gross Profit

$69.40M

Operating Income

-$83.02M

EBITDA

-$71.74M

Operating Cash Flow

-$55.81M

Capital Expenditure

-$5.60M

Free Cash Flow

-$61.41M

Cash & ST Invst.

$180.49M

Total Debt

$6.51M

Beta Bionics Performance Analysis

Beta Bionics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 179,000	N/A
2023	2023-12-31	USD 11,995,000	6601.1%
2024	2024-12-31	USD 65,124,000	442.9%
2025	2025-12-31	USD 100,251,000	53.9%

Beta Bionics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	17.3%
Q4	2025-12-31	17.9%
Q1	2026-03-31	-14.0%
Q2	2026-06-30	15.9%

Beta Bionics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.51	N/A
2023	2023-12-31	USD -1.03	-31.9%
2024	2024-12-31	USD -1.26	22.8%
2025	2025-12-31	USD -1.81	43.0%

Beta Bionics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	15.4%
Q4	2025-12-31	N/A
Q1	2026-03-31	-48.5%
Q2	2026-06-30	-8.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$32.01M

+37.8%

Gross Profit

$18.90M

+51.2%

Gross Margin

59.04%

N/A

Market Cap

$715.34M

N/A

Market Cap/Employee

$1.70M

N/A

Employees

422

N/A

Net Income

-$23.40M

-38.7%

EBITDA

-$24.46M

-50.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$180.49M

-27.7%

Total Debt

$6.51M

-2.6%

Accounts Receivable

$19.96M

+48.6%

Inventory

$23.92M

+38.1%

Long Term Debt

$4.92M

-4.8%

Short Term Debt

$1.59M

+4.7%

Return on Assets

-24.96%

N/A

Return on Invested Capital

-31.17%

N/A

Free Cash Flow

-$15.66M

-1.9%

Operating Cash Flow

-$14.62M

-7.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AHCOAdaptHealth Corp.

AHCOAdaptHealth Corp.$5.22-8.26%

TRMLTourmaline Bio, Inc.

TRMLTourmaline Bio, Inc.$47.98+0.00%

STAASTAAR Surgical Company

STAASTAAR Surgical Company$25.12+3.76%

IMTXImmatics N.V.

IMTXImmatics N.V.$9.72+0.73%

ORICORIC Pharmaceuticals, Inc.

ORICORIC Pharmaceuticals, Inc.$13.62+0.89%

KMTSKestra Medical Technologies, Ltd.

KMTSKestra Medical Technologies, Ltd.$28.35+7.39%

DVAXDynavax Technologies Corporation

DVAXDynavax Technologies Corporation$15.50+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$138.74+0.04%

ACHRArcher Aviation

ACHRArcher Aviation$6.26+0.12%

NVDANvidia

NVDANvidia$217.55-0.03%

INTCIntel

INTCIntel$97.52-0.04%

ONDSOndas

ONDSOndas$9.31+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.21+0.01%

RIGTransocean

RIGTransocean$5.72+0.09%

Questions About BBNX

What is the current price of Beta Bionics?

Beta Bionics is trading at $16.40 per share.

What is the 52-week range for Beta Bionics?

Over the past 52 weeks, Beta Bionics has traded between $8.80 and $32.71.

How much debt does Beta Bionics have?

As of the most recent reporting period, Beta Bionics reported total debt of $6.51M.

How much cash does Beta Bionics have on hand?

Beta Bionics reported $44.42M in cash and cash equivalents in its most recent financial results.

What is Beta Bionics’s dividend yield?

Beta Bionics does not currently have a dividend yield.

Beta Bionics(NASDAQ) BBNX

Beta Bionics Financials at a Glance

BBNX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Beta Bionics

What the Company Sells

Recent Growth and Partnerships

Why It Stands Out

Tracking Financial Growth

Evolution of the Business

BBNX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Beta Bionics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BBNX

What is the current price of Beta Bionics?

What is the 52-week range for Beta Bionics?

How much debt does Beta Bionics have?

How much cash does Beta Bionics have on hand?

What is Beta Bionics’s dividend yield?

Premium Investing Services